Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Zeria Pharmaceutical clinical trials
The registry lists 33 studies whose lead sponsor is Zeria Pharmaceutical or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 24, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Zeria Pharmaceutical.
- Zeria Pharmaceutical23 studiesSame company
Something wrong?
- Tillotts Pharma AG10 studies →Acquired — became part of Zeria Pharmaceutical, Sep 2009 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- A Phase III Trial of Z-338 in Paediatric Patients With Functional DyspepsiaCompletedNCT04526119Phase 3
- A Comparative Study of ZG-801 and Placebo in Patients With HyperkalemiaCompletedNCT04955678Phase 3
- Trial to Optimally Show the Pharmacological Action of Z-100CompletedNCT03476018Phase 3
- Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical CancerCompletedNCT02247232Phase 3
- Exploratory Study of ZG-801 for the Treatment of HyperkalemiaCompletedNCT03799926Phase 2
- TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC)CompletedNCT01903252Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Efficacy Study of Intravenous Iron Preparation to Iron Deficiency AnemiaCompletedNCT02731534Phase 3
- Clinical Study of Z-213 in Subjects With Iron-deficiency AnemiaCompletedNCT02828319Phase 3
- Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative ColitisCompletedNCT01059344Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Z-360 Plus GEM in Subjects With Metastatic Pancreatic AdenocarcinomaCompletedNCT02117258Phase 2
- To Evaluate Efficacy and Safety of Z-215 in Erosive EsophagitisCompletedNCT02463643Phase 2
- Phase III, Long-term, Open-label Safety Study of Z-338CompletedNCT01973790Phase 3
- Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate CapsulesCompletedNCT02911298Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Mass Balance and Metabolism Study of 14C-Z-215CompletedNCT02618629Phase 1
- To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male SubjectsCompletedNCT02509923Phase 1
- To Evaluate the Efficacy and Safety in Subjects With Functional DyspepsiaCompletedNCT00323817Phase 2
- Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency AnemiaCompletedNCT02170311Phase 1
- TP0502-B-Pharmaco-Scintigraphic-StudyCompletedNCT02306798Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- TP0501 - Pharmaco-Scintigraphic-StudyCompletedNCT02306772Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- TP0502-Pharmaco-Scintigraphic-Study and AmendmentCompletedNCT02306785Phase 1
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- A Healthy Subject Study With Z-360 and PlaceboCompletedNCT01776463Phase 1
- Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic RicketsCompletedNCT01237288Phase 3
- Comparative Efficacy and Safety Study in Patients With Active Ulcerative ColitisCompletedNCT01257386Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission PhaseCompletedNCT01257399Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted after Tillotts Pharma AG became part of Zeria Pharmaceutical
- EPANOVA in Crohn's Disease, Study 1CompletedNCT00613197Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted before Tillotts Pharma AG became part of Zeria Pharmaceutical
- Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC)CompletedNCT00731445Phase 1/2
- To Verify the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedNCT00761358Phase 3
- The Effect of Z-338 in Subjects With Functional DyspepsiaCompletedNCT00458328Phase 2
- Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine TreatmentCompletedNCT00288925Phase 1/2
- The Effects of Z-338 in Subjects With and Without Functional DyspepsiaCompletedNCT00298194Phase 2
- To Evaluate the Efficacy of Z-338 in Subjects With Functional DyspepsiaCompletedNCT00333372Phase 2
- An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseCompletedNCT00074542Phase 3
Sponsor listed in the registry: Tillotts Pharma AG · First submitted before Tillotts Pharma AG became part of Zeria Pharmaceutical
- Safety and Tolerability of Z-100 in Patients With Early HIV InfectionTerminatedNCT00016692Phase 1